富血小板血浆PRP衍生EVs递送尼拉帕尼用于超声成像和动脉粥样硬化治疗
核心信息
- 论文英文标题: Platelet-rich plasma-derived extracellular vesicles delivered niraparib for ultrasound imaging and atherosclerosis treatment
- 期刊: J Nanobiotechnology
- 发表年份: 2026
- DOI: 10.1186/s12951-026-04076-z
- PMID/PMCID: 41652437; PMC12977760
研究概览
Here, we developed NGPPEVs, a nanoplatform that employs PEVs to deliver niraparib, a PARP inhibitor, followed by encapsulation of Ca(HCO₃)₂ to generate gas within cells, thereby combining targeted therapy with ultrasound imaging capabilities. Collectively, NGPPEVs have great potential in the precise diagnosis and treatment of atherosclerosis.
核心发现
Macrophage-driven oxidative stress and chronic inflammation play pivotal roles in the progression of atherosclerosis.
Given the overactivation of poly (ADP-ribose) polymerase (PARP) in atherosclerosis, PARP inhibitors have potential therapeutic potential, but their efficacy is limited due to poor in vivo targeting.
Platelet-rich plasma-derived extracellular vesicles (PEVs), which inherently target inflammatory sites and mitigate oxidative stress, offer a promising delivery platform.
Here, we developed NGPPEVs, a nanoplatform that employs PEVs to deliver niraparib, a PARP inhibitor, followed by encapsulation of Ca(HCO₃)₂ to generate gas within cells, thereby combining targeted therapy with ultrasound imaging capabilities.
Echo Biotech 角色
Exosupur排阻柱分离PRP EVs和去除超声负载后的游离小分子
关联平台: Exoomics®, Echosome®, Research Reagents & Tools
关联服务与能力: EV Isolation & Purification, Small RNA / Cargo Loading, Research Reagent / Product Supply
关联产品或试剂: Exosupur® EV Isolation/Purification Kit
参考文献
原始论文: Platelet-rich plasma-derived extracellular vesicles delivered niraparib for ultrasound imaging and atherosclerosis treatment Journal of nanobiotechnology. 2026. DOI: 10.1186/s12951-026-04076-z. PMID/PMCID: 41652437; PMC12977760.